Related Experiment Video
Updated: Sep 26, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
[Pathophysiology of restenosis following percutaneous transluminal coronary angioplasty]
A M Holm1, S Haunsø, P R Hansen
1Medicinsk afdeling B, H:S Rigshospitalet, Hjertecentret.
Insights
Coronary restenosis after angioplasty affects 30-40% of patients. Understanding its complex mechanisms, involving smooth muscle cell proliferation and vascular remodeling, is key to developing effective therapies.
Area of Science:
- Cardiovascular biology
- Vascular medicine
- Pathophysiology
Context:
- Percutaneous transluminal coronary angioplasty (PTCA) is a common procedure.
- Symptomatic restenosis occurs in 30-40% of patients post-PTCA.
- Current pharmacological therapies are ineffective in preventing restenosis.
Purpose:
- To review the pathobiological mechanisms underlying coronary restenosis.
- To explore the sequential processes involved in neointima formation and vascular remodeling.
- To outline future therapeutic prospects for preventing restenosis.
Summary:
- Restenosis is initiated by mechanical injury during PTCA.
- It involves smooth muscle cell proliferation and extracellular matrix production.
- Mediators like growth factors and cytokines play crucial roles.
Impact:
- Improved understanding of restenosis mechanisms.
- Identification of potential therapeutic targets.
- Foundation for developing novel anti-restenosis strategies.
Abstract:
Symptomatic restenosis occurs in approximately 30-40% of patients after percutaneous transluminal coronary angioplasty (PTCA). Despite intensive research, the primary pathophysiological mediators have not been defined, and pharmacological therapy has not been effective in preventing restenosis. Restenosis is a multifactorial and sequential process, which is initiated by mechanical injury of the vessel wall, and involves neointima formation caused by the local proliferation of smooth muscle cells and production of an extracellular matrix, followed by vascular remodelling. Numerous mediators are involved in these processes, e.g., protooncogenes, growth factors, cytokines and nitric oxide. This review discusses the pathobiological mechanisms underlying coronary restenosis, and outlines the prospects for future therapy.
Related Concept Videos
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Angina II: Classification
Peripheral Artery Disease I: Introduction
Peripheral Artery Disease III: Interprofessional Care

